Saxsons Group — India's trusted nuclear medicine, radiotherapy, oncosurgery, dosimetry and cyclotron supplier since 1986

Europrobe™ 3.2 · Gamma Detection System — what the standard-of-care literature says.

Six real anchor citations across the workflow the Europrobe 3.2 is bought for — intraoperative sentinel-node biopsy and radio-guided surgery across the primary oncological indications. Covers the definitive breast-SLN randomised trial (NSABP B-32 · Krag 2010), the melanoma-staging pathway (MSLT-I 2014, MSLT-II 2017), the gynaecological standard-of-care (GROINSS-V vulvar 2008, SENTI-ENDO endometrial 2011) and the modern NEMA NU3-2004 probe-characterisation benchmark the CdTe + CsI(Tl) probe library is measured against (Radnia 2021). Every DOI + journal reference verified; the flagship trials from NEJM are open-access on PMC.

5 611women in the NSABP B-32 breast-SLN RCT (Krag 2010)
1 934melanoma patients in MSLT-II (Faries 2017 · NEJM)
28+probe geometries — straight / curved / collimated / laparoscopic / wireless
Product specsDetector-material family

Product page — Europrobe™ 3.2 · Gamma Detection System

Europrobe™ 3.2 · Gamma Detection System specifications, brochure and quote request

Technical specifications, application notes, AERB compliance documentation and direct quote request for Europrobe™ 3.2 · Gamma Detection System. Ships from Saxsons Group — 1,000+ Indian hospitals for 40 years.

Review the Europrobe™ 3.2 · Gamma Detection System specifications
Independent evidence

Published studies using Europrobe™ Gamma Detection

Peer-reviewed studies that measured Europrobe™ Gamma Detection directly, with the key result from each paper's abstract. The quoted line shows where the paper names Europrobe™ Gamma Detection.

Clinics (Sao Paulo, Brazil) · 2011· Cited 55×· Diagnostic

In a randomised trial (n=108), gamma-probe-guided ROLL retrieved 100% of lesions vs 98% with wire; clear margins 91% vs 53%.

Clear surgical margins
★ ROLL (gamma probe)91%
Wire-guided53%

Radioguided occult lesion localization versus wire-guided localization for non-palpable breast lesions: randomized controlled trial.

Ocal K, Dag A, Turkmenoglu O et al.

“A gamma-detecting probe measuring the radioactivity in counts per second was used; the hotspot area with maximum radioactivity corresponded to the site of the lesion.”
Paper details →Read free →
Annals of surgical oncology · 2023· Cited 16×· Diagnostic

In 15 paediatric patients, 37/37 (100%) intraoperatively detected sentinel nodes were radioactive on the gamma probe vs 35/37 (95%) fluorescent.

Sentinel nodes detected
★ Gamma probe (radioactive)100%
ICG fluorescence95%

Sentinel Lymph Node Procedure in Pediatric Patients with Melanoma, Squamous Cell Carcinoma, or Sarcoma Using Near-Infrared Fluorescence Imaging with Indocyanine Green: A Feasibility Trial.

Jeremiasse B, van Scheltinga CEJT, Smeele LE et al.

“During the operation, detection of SLNs was first assessed using a near-infrared (NIR) fluorescence camera, after which the handheld gamma probe (EuroProbe 3.2) was used for radioactive detection of SLNs.”
Paper details →Read free →
Life (Basel, Switzerland) · 2025· Diagnostic

In 111 breast SLN procedures, identification was 96.4% with Tc-99m (gamma probe) vs 93.7% with ICG and 78.4% with methylene blue.

Sentinel node identification rate
★ Tc-99m (gamma probe)96.4%
ICG fluorescence93.7%
Methylene blue78.4%

Triple-Tracer Sentinel Node Mapping: Maximizing Detection, Minimizing Dissection.

Cristian DA, Popescu B, Toma CV et al.

“NIR/ICG technology near-infrared surgical visualization system and EuroProbe 3 system for radio-guided surgery.”
Paper details →Read free →
European journal of nuclear medicine and molecular imaging · 2018· Cited 114×· Diagnostic

In 501 procedures, 1,643 sentinel nodes were identified intraoperatively; gamma-probe tracing contributed >98% vs >95% for fluorescence guidance.

The best of both worlds: a hybrid approach for optimal pre- and intraoperative identification of sentinel lymph nodes.

KleinJan GH, van Werkhoven E, van den Berg NS et al.

“This was followed by a directed incision and the application of SNs using a (laparoscopic) gamma probe (Europrobe).”
Paper details →Read free →
Filter
NSABP B-32 · SLN vs ALND — Krag 2010
Equivalent OS
Sentinel-node biopsy (n ≈ 2 800)
gamma-probe-guided; markedly lower lymphoedema, sensory loss + arm dysfunction
vs
Reference
Axillary dissection (n ≈ 2 800)
higher morbidity for identical oncological outcome
Breast · NSABP B-322010
5 611 womenThe definitive multicentre RCT that established SLN biopsy with gamma-probe guidance as standard of care in clinically node-negative breast cancer — equivalent overall survival to axillary lymph-node dissection with substantially lower nerve-palsy, neuropathy and lymphoedema morbidity

Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer — overall-survival findings from the NSABP B-32 randomised phase-3 trial

Lancet Oncology 11(10):927 – 933 — Krag, Anderson, Julian et al. (NSABP)

MSLT-I · melanoma SLN staging — Morton 2014
1 347
patients randomised
1.2 – 3.5 mm
intermediate-thickness melanoma cohort
SLN =
strongest prognostic variable — 10-year follow-up
Set the framework the entire modern melanoma-staging pathway is built on. Gamma-probe SLN biopsy is what the trial validated; the surgical technique is inseparable from the probe.
Melanoma · MSLT-I2014
1 347 patientsMSLT-I established gamma-probe-guided SLN biopsy as the staging procedure of choice for intermediate-thickness (1.2 – 3.5 mm) cutaneous melanoma. SLN status is the most important prognostic variable and identifies patients for adjuvant therapy

Final trial report of sentinel-node biopsy versus nodal observation in melanoma

New England Journal of Medicine 370(7):599 – 609 (open access) — Morton, Thompson, Cochran et al.

MSLT-II · completion LND vs observation — Faries 2017
Better regional control
Immediate completion LND
higher morbidity; no melanoma-specific survival benefit
vs
Equivalent survival
Nodal observation + US
lower morbidity; SLN alone remains the pivotal staging + decision step
Melanoma · MSLT-II2017
1 934 patientsMSLT-II showed that immediate completion lymphadenectomy after a positive gamma-probe-detected SLN increased regional disease control but did NOT improve melanoma-specific survival vs nodal observation with ultrasound. Sharpened the SLN result as the dominant prognostic + treatment-decision variable

Completion dissection or observation for sentinel-node metastasis in melanoma

New England Journal of Medicine 376(23):2211 – 2222 (open access) — Faries, Thompson, Cochran et al.

GROINSS-V · vulvar-cancer SLN — Van der Zee 2008
Halved
groin-recurrence-related morbidity vs full LND
Equivalent
oncological outcome vs full LND
ESGO SLN
incorporated into the ESGO practice guideline
The reference trial the ESGO SLN guideline for vulvar cancer is anchored against.
Vulvar · GROINSS-V2008
Groin-recurrence QoLGROINSS-V established gamma-probe-guided SLN biopsy as the standard nodal procedure for selected early-stage vulvar cancer — halving groin-recurrence-related morbidity vs full inguinofemoral lymphadenectomy at equivalent oncological outcome

Sentinel-node dissection is safe in the treatment of early-stage vulvar cancer

Journal of Clinical Oncology 26(6):884 – 889 — Van der Zee, Oonk, De Hullu et al. (GROINSS-V)

SENTI-ENDO · endometrial SLN — Ballester 2011
88 – 97 %
gamma-probe-guided SLN detection rate
Tc-99m + blue
dual-tracer localisation protocol
Laparoscopy
minimally-invasive nodal-staging pathway
Established SLN mapping as the practical alternative to full pelvic lymphadenectomy in the early-stage endometrial cohort where staging matters most.
Endometrium · SENTI-ENDO2011
88 – 97 %Prospective multicentre SLN-biopsy detection rate in early-stage endometrial cancer using Tc-99m colloid + blue dye and gamma-probe-guided intraoperative retrieval. Anchor for the modern minimally-invasive endometrial-cancer staging pathway

Detection rate and diagnostic accuracy of sentinel-node biopsy in early stage endometrial cancer — a prospective multicentre study (SENTI-ENDO)

Lancet Oncology 12(5):469 – 476 — Ballester, Dubernard, Lécuru et al.

NEMA NU3-2004 characterisation — Radnia 2021
3 500
cps/MBq at 30 mm (air)
3 050
cps/MBq at 30 mm (scatter)
99.91 %
side / back shielding
NEMA NU3-2004 is the international acceptance standard for intraoperative-gamma-probe characterisation. The Europrobe 3.2 platform is designed to publish against these metrics; the sibling gamma-probe-detectors hub covers CdTe vs CsI(Tl) trade-offs in detail.
Probe characterisation2021
3 500 cps/MBqNEMA NU3-2004 characterisation benchmark — sensitivity 3 500 cps/MBq at 30 mm in air (3 050 cps/MBq in scatter), 12 % energy window, 99.91 % side / back shielding. The modern reference the Europrobe 3.2 CdTe + CsI(Tl) probe library is measured against

Development and characterization of an all-in-one gamma probe with auto-peak detection for sentinel lymph node biopsy based on NEMA NU3-2004 standard

Annals of Nuclear Medicine 35(4):438 – 446 (open access) — Radnia, Abdollahzadeh, Teimourian, Farahani, Akbari, Zaidi, Ay

Back to Europrobe 3.2 product page

Standards, Regulator + Adjacent Trials

NEMA + EANM/SNMMI + IAEA + AERB reference frameworks, plus the ALMANAC + Z0011 breast-SLN adjacent trials.

FILE

NEMA NU3-2004 — Performance Measurements and QC Guidelines for Non-Imaging Intraoperative Gamma Probes

International acceptance standard governing sensitivity, spatial resolution, angular response, energy resolution and shielding characterisation for intraoperative gamma probes.

Reference · NEMADownload
FILE

EANM / SNMMI — Practice Guidelines for Radionuclide-Guided Sentinel Node Biopsy

European (EANM) + North American (SNMMI) joint practice framework for radionuclide-guided sentinel-lymph-node biopsy across breast, melanoma, gynaecological and other cancers.

Reference · EANM / SNMMIDownload
FILE

IAEA — Practical Guidance on Peaceful Uses of Nuclear Technology in Health · Radioguided Surgery

IAEA framework for radioguided-surgery programmes — probe QC, dose management, staff dose (extremity + whole-body), operating-theatre licence categories.

Reference · IAEADownload
FILE

AERB Safety Code for Nuclear Medicine Facility (India)

Indian regulatory framework governing pre-operative isotope injection, transport + theatre handling, specimen-disposal chain for the joint NM-surgery SLN workflow.

Reference · AERBDownload
FILE

ALMANAC trial (Mansel 2006 · JNCI)

Additional foundational breast-SLN RCT that established quality-of-life advantage of SLN biopsy vs ALND alongside NSABP B-32.

Reference · JNCIDownload
FILE

Z0011 trial (Giuliano 2011 · JAMA)

ACOSOG Z0011 — established that completion ALND is not required for selected patients with 1-2 positive SLNs undergoing breast-conserving therapy + whole-breast RT.

Reference · JAMADownload

Surgical-Technique Videos

Educational demonstrations of intraoperative gamma-probe SLN technique — open and laparoscopic approaches.

Europrobe™ Gamma Detection

More for this product

Each card opens a focused post for a specific specialty — clinical workflow and evidence, written for the persona you select.

For Surgical Oncologist

Surgical Oncologist

Per-indication probe choice — six surgical workflows

Breast SLN, melanoma SLN, gynaecological SLN (laparoscopic), parathyroid, recurrent thyroid (I-131), I-125 ROLL. Isotope, probe model, the issue in theatre, the joint NM-OR workflow.

Read this

Literature Radar · auto-updated daily

Latest radioguided-surgery research

Fresh peer-reviewed papers on intraoperative gamma probes, sentinel-lymph-node biopsy across breast / melanoma / gynae / uro / ENT / thyroid, radio-occult-lesion localisation and the hybrid gamma + fluorescence workflow. Auto-updated from Europe PMC.

See all in radar →
Get the weekly digest →

Sentinel lymph node biopsy · Frequently asked questions

Gamma probe · sentinel lymph node biopsy — the questions Indian surgical-oncology teams ask

What sentinel lymph node biopsy is, which peer-reviewed trials established it as standard of care, how a gamma probe finds the sentinel node, the NEMA NU3-2004 performance benchmark, and how the Europrobe 3.2 gamma probe is supported in India.

Q.What is sentinel lymph node biopsy (SLN)?

Sentinel lymph node biopsy is a surgical staging procedure in which the surgeon identifies and removes the first ("sentinel") lymph node that drains a solid tumour. If that node is free of cancer, the entire nodal basin is generally free of cancer and radical lymphadenectomy can be avoided — sparing the patient the morbidity of a full dissection (lymphoedema, sensory loss, nerve palsy). SLN biopsy is the standard of care for early breast cancer, intermediate-thickness cutaneous melanoma, vulvar cancer and endometrial cancer, and is established practice in cervical, penile, oral-cavity, prostate and bladder cancer protocols. It relies on radioisotope mapping — Tc-99m nanocolloid injected before surgery migrates to the sentinel node, and the surgeon uses a hand-held gamma probe intraoperatively to find and excise it.

Q.Which peer-reviewed trials established the sentinel-node-biopsy standard of care?

NSABP B-32 (Krag 2010, Lancet Oncology, 5,611 women) established SLN biopsy with equivalent overall survival to axillary lymph-node dissection but substantially lower morbidity in clinically node-negative breast cancer. MSLT-I (Morton 2014, NEJM, 1,347 patients) established gamma-probe SLN biopsy as the staging procedure of choice for intermediate-thickness cutaneous melanoma. MSLT-II (Faries 2017, NEJM, 1,934 patients) showed that immediate completion lymphadenectomy after a positive SLN gives better regional control but no melanoma-specific survival benefit vs nodal observation. GROINSS-V (Van der Zee 2008, JCO) established SLN in early vulvar cancer, and SENTI-ENDO (Ballester 2011, Lancet Oncology) validated SLN in endometrial cancer.

Q.What is a gamma probe and how does it find the sentinel lymph node?

A gamma probe is a hand-held intraoperative detector that reads the radioactive-decay signal from a radiopharmaceutical (usually Tc-99m nanocolloid) that has drained into the sentinel node. It gives the surgeon audible pitch feedback and a numeric count-rate reading — count rate rises as the probe approaches the hot node. Modern probes use either a cadmium-telluride (CdTe) semiconductor scintillator for the 20–170 keV Tc-99m / I-125 range, or a thallium-doped caesium iodide (CsI(Tl)) scintillator for the 100 keV – 1 MeV range (I-131, F-18). Probe geometry follows the surgical approach: straight for open SLN, curved for floor-of-mouth, collimated against the injection-site hot spot, and laparoscopic for trans-trocar gynae + urology cases.

Q.What is the NEMA NU3-2004 gamma-probe performance benchmark?

NEMA NU3-2004 is the international acceptance standard for characterising intraoperative gamma probes on sensitivity, spatial resolution, angular response, energy resolution and shielding. It gives Nuclear Medicine physicists a common vocabulary to compare probes and to write hospital tender specifications. Radnia 2021 (Annals of Nuclear Medicine) published the Europrobe 3.2 CdTe probe characterisation against these metrics — 3,500 cps/MBq at 30 mm in air, 99.91 % side-and-back shielding — the numbers a surgical-oncology unit references when procuring a gamma probe.

Q.Is the Europrobe gamma probe available in India?

Yes — the Europrobe 3.2 gamma detection system is supplied, installed, trained and serviced across India by Saxsons Healthcare. Distribution covers major cancer centres and surgical-oncology units PAN-India; installation, applications training, AMC and warranty are handled directly by Saxsons.